{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:48Z","timestamp":1794009108986,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14512-2","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:44:55Z","timestamp":1768441495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in advanced pancreatic cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"David","family":"Easty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar S.","family":"Breathnach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemer","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Donachie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shevlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine J.","family":"Farr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"1","key":"14512_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14512_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/path.4172","volume":"230","author":"R Kadaba","year":"2013","unstructured":"Kadaba R, Birke H, Wang J, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013;230(1):107\u201317.","journal-title":"J Pathol"},{"issue":"10","key":"14512_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/annonc\/mdt239","volume":"24","author":"V Heinemann","year":"2013","unstructured":"Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24(10):2484\u201392.","journal-title":"Ann Oncol"},{"issue":"18","key":"14512_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"31","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med Oct. 2013;31(18):1691\u2013703.","journal-title":"N Engl J Med Oct"},{"issue":"1","key":"14512_CR5","doi-asserted-by":"publisher","first-page":"e2350756","DOI":"10.1001\/jamanetworkopen.2023.50756","volume":"7","author":"F Nichetti","year":"2024","unstructured":"Nichetti F, Rota S, Ambrosini P, et al. NALIRIFOX, FOLFIRINOX, and gemcitabine with Nab-Paclitaxel as First-Line chemotherapy for metastatic pancreatic cancer: A systematic review and Meta-Analysis. JAMA Netw Open Jan. 2024;7(1):e2350756.","journal-title":"JAMA Netw Open Jan"},{"issue":"6","key":"14512_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccr.2014.05.026","volume":"16","author":"J Gore","year":"2014","unstructured":"Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer Cell Jun. 2014;16(6):711\u20132.","journal-title":"Cancer Cell Jun"},{"issue":"25","key":"14512_CR7","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1016\/j.cell.2021.11.017","volume":"9","author":"S Raghavan","year":"2021","unstructured":"Raghavan S, Winter PS, Navia AW, et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell Dec. 2021;9(25):6119\u2013e61376126.","journal-title":"Cell Dec"},{"issue":"4","key":"14512_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0513-2","volume":"32","author":"Y Xu","year":"2015","unstructured":"Xu Y, Li H, Huang C, et al. Wnt2 protein plays a role in the progression of pancreatic cancer promoted by pancreatic stellate cells. Med Oncol. 2015;32(4): 97.","journal-title":"Med Oncol"},{"issue":"1","key":"14512_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2019.05.012","volume":"27","author":"M Ligorio","year":"2019","unstructured":"Ligorio M, Sil S, Malagon-Lopez J, et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic Cancer. Cell Jun. 2019;27(1):160\u201375. e127.","journal-title":"Cell Jun"},{"issue":"3","key":"14512_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"1","author":"RF Hwang","year":"2008","unstructured":"Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res Feb. 2008;1(3):918\u201326.","journal-title":"Cancer Res Feb"},{"issue":"6","key":"14512_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"16","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell Jun. 2014;16(6):735\u201347.","journal-title":"Cancer Cell Jun"},{"issue":"6","key":"14512_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ccell.2015.11.002","volume":"14","author":"BC Ozdemir","year":"2015","unstructured":"Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of Carcinoma-Associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas Cancer with reduced survival. Cancer Cell Dec. 2015;14(6):831\u20133.","journal-title":"Cancer Cell Dec"},{"issue":"4","key":"14512_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Kim J, Yang S, et al. Type I collagen deletion in alphaSMA(+) myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell Apr. 2021;12(4):548\u2013e565546.","journal-title":"Cancer Cell Apr"},{"issue":"36","key":"14512_CR14","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","volume":"20","author":"DV Catenacci","year":"2015","unstructured":"Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase ib\/ii study of gemcitabine plus placebo or vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic Cancer. J Clin Oncol Dec. 2015;20(36):4284\u201392.","journal-title":"J Clin Oncol Dec"},{"issue":"3","key":"14512_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/MPA.0000000000000458","volume":"45","author":"AH Ko","year":"2016","unstructured":"Ko AH, LoConte N, Tempero MA, et al. A phase I study of FOLFIRINOX plus IPI-926, a Hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 2016;45(3):370\u20135.","journal-title":"Pancreas"},{"issue":"10","key":"14512_CR16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168\u201378.","journal-title":"Nat Genet"},{"issue":"6","key":"14512_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1136\/gutjnl-2018-317706","volume":"68","author":"C Maurer","year":"2019","unstructured":"Maurer C, Holmstrom SR, He J, et al. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut. 2019;68(6):1034\u201343.","journal-title":"Gut"},{"issue":"2","key":"14512_CR18","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Oni TE, Spielman B, et al. IL1-Induced JAK\/STAT signaling is antagonized by TGFbeta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov Feb. 2019;9(2):282\u2013301.","journal-title":"Cancer Discov Feb"},{"issue":"5","key":"14512_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-19-0273","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi G, Tuveson DA. A fatal combination: Fibroblast-derived lipids and cancer-derived autotaxin promote pancreatic cancer growth. Cancer Discov. 2019;9(5):578\u201380.","journal-title":"Cancer Discov"},{"issue":"7934","key":"14512_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty AT, Shyer JA, Thai M, et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611(7934):148\u201354.","journal-title":"Nature"},{"issue":"1","key":"14512_CR21","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1038\/s41467-022-30484-4","volume":"19","author":"KW Lee","year":"2022","unstructured":"Lee KW, Yeo SY, Gong JR, et al. PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. Nat Commun May. 2022;19(1):2793.","journal-title":"Nat Commun May"},{"issue":"1","key":"14512_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"Werba G, Weissinger D, Kawaler EA, et al. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat Commun. 2023;14(1):797. https:\/\/doi.org\/10.1038\/s41467-023-36296-4.","journal-title":"Nat Commun"},{"issue":"3","key":"14512_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4161\/cbt.7.3.5418","volume":"7","author":"GG Schwartz","year":"2008","unstructured":"Schwartz GG, Eads D, Naczki C, et al. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther Mar. 2008;7(3):430\u20136.","journal-title":"Cancer Biol Ther Mar"},{"issue":"1","key":"14512_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"25","author":"MH Sherman","year":"2014","unstructured":"Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell Sep. 2014;25(1):80\u201393.","journal-title":"Cell Sep"},{"issue":"4","key":"14512_CR25","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s10637-008-9184-6","volume":"27","author":"CD Blanke","year":"2009","unstructured":"Blanke CD, Beer TM, Todd K, et al. Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest New Drugs. 2009;27(4):374\u20138.","journal-title":"Invest New Drugs"},{"issue":"17","key":"14512_CR26","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1158\/1078-0432.CCR-13-3247","volume":"1","author":"J Medioni","year":"2014","unstructured":"Medioni J, Deplanque G, Ferrero JM, et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res Sep. 2014;1(17):4471\u20137.","journal-title":"Clin Cancer Res Sep"},{"key":"14512_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS784","author":"K Perez","year":"2020","unstructured":"Perez K, Cleary JM, Karasic TB, et al. Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. J Clin Oncol. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.TPS784.","journal-title":"J Clin Oncol"},{"key":"14512_CR28","doi-asserted-by":"crossref","unstructured":"Borazanci E, Jameson GS, Sharma S, et al. A phase II pilot trial of nivolumab (N)\u2009+\u2009albumin bound paclitaxel (AP)\u2009+\u2009paricalcitol (P)\u2009+\u2009cisplatin (C)\u2009+\u2009gemcitabine (G) (NAPPCG) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Cancer. 2021;81.","DOI":"10.1158\/1538-7445.PANCA21-PR-002"},{"issue":"5","key":"14512_CR29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1620164114","volume":"31","author":"MH Sherman","year":"2017","unstructured":"Sherman MH, Yu RT, Tseng TW, et al. Stromal cues regulate the pancreatic cancer epigenome and metabolome. Proc Natl Acad Sci U S Jan. 2017;31(5):1129\u201334.","journal-title":"Proc Natl Acad Sci U S Jan"},{"issue":"3","key":"14512_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"14512_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/0091270011412966","volume":"52","author":"PA Noertersheuser","year":"2012","unstructured":"Noertersheuser PA, Pradhan RS, Klein CE, et al. Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis. J Clin Pharmacol. 2012;52(8):1162\u201373.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"14512_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"issue":"11","key":"14512_CR33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1158\/1541-7786.MCR-15-0204","volume":"13","author":"MD Arensman","year":"2015","unstructured":"Arensman MD, Nguyen P, Kershaw KM, et al. Calcipotriol targets LRP6 to inhibit Wnt signaling in pancreatic cancer. Mol Cancer Res. 2015;13(11):1509\u201319.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"14512_CR34","doi-asserted-by":"publisher","first-page":"17444","DOI":"10.1038\/s41598-020-74368-3","volume":"15","author":"L Gorchs","year":"2020","unstructured":"Gorchs L, Ahmed S, Mayer C, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep Oct. 2020;15(1):17444.","journal-title":"Sci Rep Oct"},{"key":"14512_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1.","journal-title":"Lancet"},{"key":"14512_CR36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1405","author":"PM Grierson","year":"2023","unstructured":"Grierson PM, Suresh R, Tan B, et al. A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU\/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1405.","journal-title":"Clin Cancer Res"},{"key":"14512_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4154","author":"VM Chung","year":"2018","unstructured":"Chung VM, Borazanci EH, Jameson GS, et al. A SU2C catalyst randomized phase II trial of pembrolizumab with or without paricalcitol in patients with stage IV pancreatic cancer who have been placed in best possible response. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS4154.","journal-title":"J Clin Oncol"},{"issue":"1","key":"14512_CR38","doi-asserted-by":"publisher","first-page":"oyae323","DOI":"10.1093\/oncolo\/oyae323","volume":"30","author":"V Chung","year":"2025","unstructured":"Chung V, Alistar A, Becerra, et al. Pembrolizumab\u2009\u00b1\u2009paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025;30(1):oyae323.","journal-title":"Oncologist"},{"issue":"5","key":"14512_CR39","doi-asserted-by":"publisher","first-page":"e48780","DOI":"10.15252\/embr.201948780","volume":"6","author":"A Steins","year":"2020","unstructured":"Steins A, van Mackelenbergh MG, van der Zalm AP, et al. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep May. 2020;6(5):e48780.","journal-title":"EMBO Rep May"},{"issue":"1","key":"14512_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-022-02301-9","volume":"10","author":"T Shinkawa","year":"2022","unstructured":"Shinkawa T, Ohuchida K, Mochida Y, et al. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. J Exp Clin Cancer Res Mar. 2022;10(1):89.","journal-title":"J Exp Clin Cancer Res Mar"},{"issue":"3","key":"14512_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"1","author":"T Seino","year":"2018","unstructured":"Seino T, Kawasaki S, Shimokawa M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell Mar. 2018;1(3):454\u2013e467456.","journal-title":"Cell Stem Cell Mar"},{"issue":"52","key":"14512_CR42","doi-asserted-by":"publisher","first-page":"26835","DOI":"10.1073\/pnas.1914915116","volume":"116","author":"RL Porter","year":"2019","unstructured":"Porter RL, Magnus NKC, Thapar V, et al. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2019;116(52):26835\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"14512_CR43","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","volume":"1","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic Cancer. Clin Cancer Res Aug. 2015;1(15):3561\u20138.","journal-title":"Clin Cancer Res Aug"},{"issue":"1","key":"14512_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jmedchem.0c01197","volume":"14","author":"Z Kang","year":"2021","unstructured":"Kang Z, Wang C, Tong Y, et al. Novel nonsecosteroidal vitamin D receptor modulator combined with gemcitabine enhances pancreatic Cancer therapy through remodeling of the tumor microenvironment. J Med Chem Jan. 2021;14(1):629\u201343.","journal-title":"J Med Chem Jan"},{"issue":"7","key":"14512_CR45","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s10620-023-07931-3","volume":"68","author":"D Wei","year":"2023","unstructured":"Wei D, Wang L, Liu Y, et al. Activation of vitamin D\/VDR signaling reverses gemcitabine resistance of pancreatic cancer cells through inhibition of MUC1 expression. Dig Dis Sci. 2023;68(7):3043\u201358.","journal-title":"Dig Dis Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14512-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14512-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:09:13Z","timestamp":1771430953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-14512-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14512"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14512-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"12 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Health Products Regulatory Authority and the National Research Ethics Committee. All patients provided informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}